Profil bibliographique

Don A. Stevens

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

206Publications signalées

7179Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Publications récentes

2026 articleOpenAlex

ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical Trial

Mehdi Hamadani, Houston Holmes, James Essell, Ayad Hamdan et autres

2 citationsTransplantation and Cellular Therapy

2025 conference-abstractOpenAlex

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Tae‐Min Kim, Jing‐Zhou Hou, Sameh Gaballa, Ranjit Nair et autres

3 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Philippe Armand, Seung‐Tae Lee, Wojciech Jurczak, Don A. Stevens et autres

1 citationBlood

2025 conference-abstractOpenAlex

Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study

José C. Villasboas, Deepa Jagadeesh, Don A. Stevens, Michał Taszner et autres

2 citationsBlood

2025 conference-abstractOpenAlex

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

John M. Burke, Nancy L. Bartlett, Gary Simmons, Lindsey Fitzgerald et autres

1 citationBlood

Accès ouvert 2025 conference-abstractOpenAlex

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Paolo Ghia, Barbara Eichhorst, Tomasz Wróbel, İnci Alacacıoğlu et autres

1 citationBlood

2025 conference-abstractOpenAlex

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Jing‐Zhou Hou, Tae Min Kim, Seok‐Goo Cho, Sameh Gaballa et autres

1 citationBlood

2025 conference-abstractOpenAlex

Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype

Lauren E. Merz, Gilles Attipoe, Christina M. Barriteau, Michael Blechner et autres

1 citationBlood

2025 articleOpenAlex

ABCL-1113: Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ranjit Nair, Tae Min Kim, Dok Hyun Yoon, Sameh Gaballa et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2025 articleOpenAlex

POSTER: ABCL-1113 Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ranjit Nair, Tae Min Kim, Dok Hyun Yoon, Sameh Gaballa et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.